Ezra Expands Its Full-Body Cancer Screening Service to California

Share Article

AI Healthcare Company Introduces its Technology to San Francisco and Los Angeles

Ezra, the healthcare artificial intelligence (AI) company creating a new standard for early cancer detection, has announced the rollout of eight new MRI-based cancer screening locations in California, in partnership with RadNet, Inc. (NASDAQ: RDNT), the largest outpatient imaging network in the United States. This marks the Company’s largest expansion beyond its East Coast footprint of New York and New Jersey—and doubles the number of facilities. Ezra’s advanced full-body MRI scan detects cancer, precancerous lesions, and actionable disease states—aneurysms, polyps, cysts, and more.

“At Ezra, our mission is to help people detect cancer at its earliest stages - before it spreads,” said Ezra CEO Emi Gal. “I am thrilled to announce the rollout of eight new centers across San Francisco and Los Angeles, making early detection a reality for more people than ever. We are excited to introduce Ezra to California and impact lives with the peace of mind that comes from getting screened.”

Of the eight new California locations, four will be in Los Angeles, three in the San Francisco Bay Area, and one in San Jose. “We’re proud to be a partner in bringing Ezra’s technology to the West Coast,” said Dr. Howard Berger, RadNet CEO. “Artificial Intelligence will have an important impact on the future of medical imaging, and we are excited to be innovating with Ezra.”

The American Cancer Society estimates that in 2018, over 178,000 new cases of cancer were diagnosed in California alone, and cancer is responsible for over 60,000 deaths each year in the state . Ezra screens for cancer and precancerous states by using state-of-the-art MRI technology, with a protocol that can find cancer and precancerous lesions in up to 13 organs in women and 11 for men. Ezra’s lung and breast protocols use various imaging modalities—and are offered to high-risk individuals.

Since launching in January 2019, Ezra has helped 11% of its members identify cancer, 32% of its male members avoid an unnecessary prostate biopsy, and 51% of its members detect other clinically significant health conditions (e.g. aneurysms, hernia, fatty liver disease, etc.).

Ezra is also developing a novel Prostate AI designed to assist radiologists in identifying lesions in the prostate faster—and with greater accuracy. A study published by Ezra in the peer-reviewed Journal of Computer Assisted Radiology and Surgery showed that the company’s Prostate AI has 93% accuracy in detecting prostate cancer lesions on multi-parametric MR images2.

In the eight months since its launch, Ezra has garnered backing from a board of leading medical advisors, including Columbia University’s Dr. Azra Raza, Dr. Siddhartha Mukherjee - Pulitzer Prize winning author of “The Emperor Of All Maladies”, Dr. Joseph Alukal, Dr. Oguz Akin from Memorial Sloan Kettering Cancer Center, Dr. Lawrence N. Tanenbaum of RadNet, Inc., Dr. John Melnick and Dr. Charles Fiske.

About Ezra

Ezra is a technology company dedicated to providing early cancer detection by pairing the most advanced medical imaging with Artificial Intelligence. We offer a full-body MRI scan in a single session, and we are building Artificial Intelligence, the Ezra AI, to assist radiologists in their workflow and enable them to quickly and accurately diagnose potential abnormalities anywhere in the body.

The Ezra AI is an investigational device that has not yet received marketing authorization from the Food and Drug Administration (“FDA”). The safety and effectiveness of the device have not yet been established. After further study of our technology, we plan to seek FDA clearance in the second half of 2019 and subsequently make the Ezra AI available to radiologists.

Ezra is headquartered in New York City, with R&D operations in Toronto.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Christina Halper Gorini
Victory Public Relations
+1 (732) 496-1118
Email >
Visit website